Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.56 |
| ▸ | COMT | P21964 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | UQCRB | P14927 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674171 | 0.83 | COMT (0.41) | FTOCOMTHTR6KDM4ESMN1; SMN2 | |
| SCHEMBL20674168 | 0.81 | COMT (0.39) | FTOCOMTHTR6KDM4EALDH1A1 | |
| SCHEMBL20674181 | 0.80 | FTO (0.54) | FTOCOMTHTR6KDM4ESMN1; SMN2 | |
| SCHEMBL20674170 | 0.75 | FTO (0.43) | FTOHTR6KDM4EALDH1A1MEN1 | |
| SCHEMBL20674020 | 0.73 | FTO (0.49) | FTOCOMTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20674553 | 0.73 | GLO1 (0.54) | FTOKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL18218267 | 0.72 | FTO (1.00) | FTOCOMTKDM4EUQCRB | |
| SCHEMBL20674512 | 0.71 | HTT (0.46) | COMTKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL4178176 | 0.70 | MAPT (0.62) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20674177 | 0.69 | KDM4E (0.41) | FTOKDM4EALDH1A1SMN1; SMN2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | FTO 4313/4885COMT 2706/4885HTR6 3906/4885 |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | FTO 4454/4885COMT 2571/4885HTR6 3946/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | FTO 4313/4885COMT 2706/4885HTR6 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.